Two different spectrofluorimetric methods for simultaneous determination of gemfibrozil and rosiglitazone in human plasma.
Two accurate, reliable, and highly sensitive spectrofluorimetric methods were developed for simultaneous determination of binary mixture gemfibrozil and rosiglitazone in human plasma without prior separation steps. The first method is based on synchronous fluorescence spectrometry using double scans. At Δλ=27nm, gemfibrozil yields detectable signal that is independent of the presence of rosiglitazone. Similarly, at Δλ=120nm the signal of rosiglitazone is not influenced by the presence of gemfibrozil. Signals at two wavelengths, 301 (Δλ=27nm) and 368nm (Δλ=120nm) vary linearly with gemfibrozil and rosiglitazone concentrations over the range 100-700ngmL(-1) (for gemfibrozil) and 20-140ngmL(-1) (for rosiglitazone), respectively. The limits of detection (LOD) were 2.3 and 2.72ngmL(-1) for gemfibrozil and rosiglitazone, respectively. The second method is based on the technique of simultaneous equations (Vierodt's method), in which 258nm was selected as the excitation wavelength. Two equations are constructed based on the fact that at ( λ(EM)₂=302 nm of gemfibrozil) and (λ(EM)₂=369 nm of rosiglitazone) the fluorescence of the mixture is the sum of the individual fluorescence of gemfibrozil and rosiglitazone. The limits of detection (LOD) were 28.1 and 23.63ngmL(-1) for gemfibrozil and rosiglitazone, respectively. The proposed methods were successfully applied for the determination of the two compounds in synthetic mixtures and in human plasma with a good recovery.
El-Din
Mohie M K Sharaf
MM
Department of Pharmaceutical Analytical Chemistry, College of Pharmacy, Mansoura University, Mansoura, Egypt.
Attia
Khalid A M
KA
Nassar
Mohamed W I
MW
Kaddah
Mohamed M Y
MM
D002021:Buffers; D002138:Calibration; D015248:Gemfibrozil / Q000097:blood*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007004:Hypoglycemic Agents / Q000097:blood*; D066298:In Vitro Techniques; D012015:Reference Standards; D015203:Reproducibility of Results; D000077154:Rosiglitazone; D012680:Sensitivity and Specificity; D012996:Solutions; D013050:Spectrometry, Fluorescence / Q000379:methods*; D045162:Thiazolidinediones / Q000097:blood*
D002021:Buffers; D007004:Hypoglycemic Agents; D012996:Solutions; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D015248:Gemfibrozil